AstraZeneca Defends Crestor Again; Circulation Publishes Safety Analysis
Executive Summary
A medical journal article suggesting a higher risk of muscle and kidney toxicity associated with Crestor compared to other statins is misleading and in "direct contrast" to FDA's position, AstraZeneca said May 23